drugset / Trial / NCT05522985
Toripalimab-based Neoadjuvant Therapy in LA-HNSCC
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of research is to evaluate the efficacy and safety of Toripalimab combined with AP regimen in the treatment of resectable locally advanced head and neck squamous cell carcinoma.122 patients were randomly divided into two groups: the test group (Toripalimab combined with AP ) and the control group (AP ); The patients in both groups were treated with three cycles of induction therapy. After the induction therapy, the patients were evaluated and followed up with surgery.
Timeline
- Start
- 2022-09-02
- Primary completion
- 2023-12-07
- Completion
- 2027-11-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Nab-paclitaxel | Small molecule | 260 mg/m2 | Intravenous |